

Brilliant Violet 421™ anti-mouse CD279 (PD-1) Antibody

Catalog# / Size	135217 / 125 µL 135221 / 50 µg 135218 / 500 µL
Clone	29F.1A12
Regulatory Status	RUO
Other Names	PD-1, Programmed Death-1
Isotype	Rat IgG2a, κ
Description	CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested SB - Reported in the literature, not verified in house
Recommended Usage	<p>Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.</p> <p>Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.</p> <p>Learn more about Brilliant Violet™.</p> <p>This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.</p>
Excitation Laser	Violet Laser (405 nm)

Application Notes	Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue ³ , <i>in vivo</i> blocking of PD-1 binding to its ligands ^{2,3} , and spatial biology (IBEX) ^{5,6} .
Additional Product Notes	Iterative Bleaching Extended multi-plexity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
Application References	<ol style="list-style-type: none"> 1. Good-Jacobson KL, <i>et al.</i> 2010. <i>Nat. Immunol.</i> 11:535. (FC) PubMed 2. Lázár-Molnár E, <i>et al.</i> 2008. <i>Proc. Natl. Acad. Sci. USA</i> 105:2658. (Block) 3. Liang SC, <i>et al.</i> 2003. <i>Eur. J. Immunol.</i> 33:2706. (FC, IHC, Block) 4. Tobias J, <i>et al.</i> 2020. <i>Front Immunol.</i> 11:895 (FC, ELISA) PubMed 5. Radtke AJ, <i>et al.</i> 2020. <i>Proc Natl Acad Sci U S A.</i> 117:33455-65. (SB) PubMed 6. Radtke AJ, <i>et al.</i> 2022. <i>Nat Protoc.</i> 17:378-401. (SB) PubMed
Product Citations	<ol style="list-style-type: none"> 1. Kinsey G, <i>et al.</i> 2012. <i>J Am Soc Nephrol.</i> 23:1528. PubMed 2. Kim Y, <i>et al.</i> 2015. <i>PLoS One.</i> 10:120294. PubMed 3. Wan X, Thomas J, Unanue E 2016. <i>J Exp Med.</i> 213: 967 - 978. PubMed 4. Scala M, <i>et al.</i> 2016. <i>J Virol.</i> 90: 8563 - 8574. PubMed 5. RY H, <i>et al.</i> 2016. <i>Oncimmunology.</i> 6:e1249561. PubMed 6. Ye Y, <i>et al.</i> 2020. <i>Genome Med.</i> 0.557638889. PubMed 7. Clemmensen HS, <i>et al.</i> 2020. <i>Front Immunol.</i> 11:585359. PubMed 8. Calvo-Barreiro L, <i>et al.</i> 2021. <i>Neurotherapeutics.</i> . PubMed 9. Nicolas-Boluda A, <i>et al.</i> 2021. <i>eLife.</i> 10:00. PubMed 10. Kumagai S, <i>et al.</i> 2020. <i>Immunity.</i> 53(1):187-203.e8. PubMed 11. Gonzalez-Figueroa P, <i>et al.</i> 2021. <i>Cell.</i> 184(7):1775-1789.e19. PubMed 12. Delacher M, <i>et al.</i> 2021. <i>Immunity.</i> 54(4):702-720.e17. PubMed 13. Wong HS, <i>et al.</i> 2021. <i>Cell.</i> . PubMed 14. Martínez-López M <i>et al.</i> 2019. <i>Immunity.</i> 50(2):446-461 . PubMed 15. Nagai Y, <i>et al.</i> 2019. <i>Front Immunol.</i> 10:174. PubMed 16. Tavazoie MF, <i>et al.</i> 2018. <i>Cell.</i> 172:825. PubMed 17. Wei SC, <i>et al.</i> 2019. <i>Immunity.</i> 50:1084. PubMed 18. Papa I, <i>et al.</i> 2017. <i>Nature.</i> 547:318. PubMed 19. Pein M, <i>et al.</i> 2020. <i>Nat Commun.</i> 11:1494. PubMed 20. Liu H, <i>et al.</i> 2020. <i>Cancer Cell.</i> 37(3):324-339. PubMed
RRID	<p>AB_10900085 (BioLegend Cat. No. 135217)</p> <p>AB_2562568 (BioLegend Cat. No. 135221)</p> <p>AB_2561447 (BioLegend Cat. No. 135218)</p>

Antigen Details



Structure	A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution	Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.
Function	Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor	B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type	B cells, T cells
Biology Area	Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family	CD Molecules, Immune Checkpoint Receptors
Antigen References	<ol style="list-style-type: none"> 1. Nishimura H, <i>et al.</i> 2001. <i>Science</i> 291:319 2. Agata Y, <i>et al.</i> 1996. <i>Int. Immunol.</i> 8:765 3. Liang SC, <i>et al.</i> 2003. <i>Eur. J. Immunol.</i> 33:2706 4. Barber DL, <i>et al.</i> 2006. <i>Nature</i> 439:682 5. Keir ME, <i>et al.</i> 2005. <i>J. Immunol.</i> 175:7372 6. Koehn BH. <i>et al.</i> 2008. <i>J Immunol.</i> 181:5313
Gene ID	18566

Related Protocols


Other Formats

PE/Dazzle™ 594 anti-mouse CD279 (PD-1), Alexa Fluor® 647 anti-mouse CD279 (PD-1), Brilliant Violet 711™ anti-mouse CD279 (PD-1), GolnVivo™ Purified anti-mouse CD279 (PD-1), APC/Fire™ 750 anti-mouse CD279 (PD-1), Brilliant Violet 510™ anti-mouse CD279 (PD-1), Ultra-LEAF™ Purified anti-mouse CD279 (PD-1), APC/Fire™ 810 anti-mouse CD279 (PD-1) Antibody, PE/Fire™ 810 anti-mouse CD279 (PD-1) Antibody, PE/Cyanine5 anti-mouse CD279 (PD-1), Purified anti-mouse CD279 (PD-1), PE anti-mouse CD279 (PD-1), PerCP/Cyanine5.5 anti-mouse CD279 (PD-1), APC anti-mouse CD279 (PD-1), Biotin anti-mouse CD279 (PD-1), FITC anti-mouse CD279 (PD-1), PE/Cyanine7 anti-mouse CD279 (PD-1), Brilliant Violet 421™ anti-mouse CD279 (PD-1), Brilliant Violet 605™ anti-mouse CD279 (PD-1), APC/Cyanine7 anti-mouse CD279 (PD-1), Brilliant Violet 785™ anti-mouse CD279 (PD-1)

Product Data



Con-A and IL-2 stimulated C57BL/6 splenocytes (3 days) were stained with CD3 APC and CD279 (clone 29F.1A12) Brilliant Violet 421™ (top), or rat IgG2a, κ Brilliant Violet 421™ isotype control (bottom).



Mice were injected subcutaneously with sheep red blood cells in a volume of 25 μl per site on days 0 and 4 and harvested on day 11. Confocal image of C57BL/6 mouse lymph node acquired using the IBEX method of highly multiplexed antibody-based imaging: PD-1 (green) in Cycle 1, CD23 (magenta) in Cycle 7, and IgD (blue) in Cycle 10. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

